Your browser is no longer supported. Please, upgrade your browser.
NXTC NextCure, Inc. weekly Stock Chart
NXTC [NASD]
NextCure, Inc.
Index- P/E- EPS (ttm)-1.10 Insider Own13.53% Shs Outstand27.51M Perf Week-51.18%
Market Cap254.06M Forward P/E- EPS next Y-2.58 Insider Trans0.00% Shs Float23.78M Perf Month-61.75%
Income-17.80M PEG- EPS next Q-0.52 Inst Own82.60% Short Float8.92% Perf Quarter-76.22%
Sales27.40M P/S9.27 EPS this Y-106.80% Inst Trans0.67% Short Ratio4.13 Perf Half Y-82.54%
Book/sh12.06 P/B0.75 EPS next Y-62.30% ROA-6.40% Target Price- Perf Year-45.20%
Cash/sh11.51 P/C0.79 EPS next 5Y- ROE-7.10% 52W Range8.00 - 109.00 Perf YTD-83.88%
Dividend- P/FCF- EPS past 5Y- ROI-11.50% 52W High-91.73% Beta-
Dividend %- Quick Ratio40.10 Sales past 5Y- Gross Margin- 52W Low12.63% ATR2.54
Employees69 Current Ratio40.10 Sales Q/Q1549.10% Oper. Margin-81.90% RSI (14)17.71 Volatility20.42% 11.54%
OptionableYes Debt/Eq0.01 EPS Q/Q218.20% Profit Margin-65.20% Rel Volume4.56 Prev Close9.08
ShortableNo LT Debt/Eq0.01 Earnings- Payout- Avg Volume513.75K Price9.01
Recom2.10 SMA20-56.42% SMA50-66.94% SMA200-76.45% Volume1,920,477 Change-0.77%
Jul-13-20Downgrade SunTrust Buy → Hold
Jul-13-20Downgrade ROTH Capital Buy → Neutral
Jun-01-20Downgrade The Benchmark Company Buy → Hold
Jun-01-20Downgrade BofA/Merrill Buy → Neutral $62 → $40
May-26-20Initiated JMP Securities Mkt Outperform $55
Mar-24-20Initiated The Benchmark Company Buy $55
Mar-02-20Initiated ROTH Capital Buy $80
Jan-13-20Initiated SunTrust Buy $78
Dec-05-19Initiated Needham Buy
Nov-26-19Initiated BTIG Research Buy $61
Jul-09-19Initiated BofA/Merrill Buy $25
Jun-03-19Initiated Piper Jaffray Overweight $26
Jun-03-19Initiated Morgan Stanley Overweight $25
Jul-13-20 06:05AM  
Jul-07-20 04:05PM  
Jun-27-20 09:56PM  
May-29-20 08:05AM  
May-28-20 02:55PM  
May-07-20 06:45PM  
05:10PM  
May-06-20 08:05AM  
Apr-15-20 12:28PM  
Apr-13-20 07:05AM  
Apr-08-20 07:05AM  
Mar-30-20 07:05AM  
Mar-26-20 08:52AM  
Mar-12-20 05:00PM  
Feb-25-20 08:05AM  
Feb-18-20 08:05AM  
Jan-14-20 03:12PM  
Jan-06-20 04:10PM  
Dec-22-19 05:05AM  
Dec-16-19 06:11AM  
Nov-26-19 08:05AM  
Nov-19-19 04:05PM  
Nov-15-19 10:09AM  
Nov-14-19 10:10PM  
Nov-12-19 04:18PM  
03:25PM  
08:05AM  
Nov-11-19 01:37PM  
10:53AM  
Nov-09-19 05:05PM  
Nov-04-19 08:05AM  
Nov-01-19 04:24PM  
Oct-02-19 07:30AM  
Oct-01-19 06:20PM  
Sep-03-19 04:05PM  
Aug-12-19 04:05PM  
Aug-08-19 06:02AM  
Jul-18-19 11:20AM  
Jun-10-19 04:05PM  
May-08-19 08:46PM  
May-04-19 05:25PM  
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is headquartered in Beltsville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Liu LindaSVP, ResearchNov 27Option Exercise0.7555,23441,65655,234Feb 21 04:11 PM
Sofinnova Venture Partners IX,10% OwnerNov 15Buy36.75150,0005,512,5002,671,856Nov 19 09:47 PM